FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma

Oncology Reports

Volumn 23, Issue 3, 2010, Pages 739-744

  Tanuma, Jun Ichi ^a   Izumo, Toshiyuki ^b   Hirano, Masato ^a   Oyazato, Yoshitaka ^a   Hori, Fumiya ^a   Umemura, Eri ^a   Shisa, Hayase ^b   Hiai, Hiroshi ^c   Kitano, Motoo ^d  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c Shiga Medical Center   (Japan)

^d Nakatsu Municipal Hospital   (Japan)

Author keywords

Fibroblast growth factor receptor 4; Oral squamous cell carcinoma; Polymorphism; TP53

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; GENES, P53; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4;

EID: 77349112658     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000692     Document Type: Article

References (32)

1. American Cancer Society Cancer facts and figures, 2006 Report. Available from: http://www.cancer.org/
2. Zhang Y, Hiraishi Y, Wang H, et al: Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer 17: 166-168, 2005.
3. Aubertin J, Tourpin S, Janot F, Ahomadegbe JC and Radvanyi F: Analysis of fibroblast growth factor receptor 3 G697C mutation in oral squamous cell carcinomas. Int J Cancer 120: 2058-2059, 2007.
4. Powers CJ, McLeskey SW and Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7: 165-197, 2000.
5. Beau-Faller M, Gaub MP, Schneider A, et al: Allelic imbalance at loci containing FGFR, FGF, c-Met and HGF candidate genes in non-small cell lung cancer sub-types, implication for progression. Eur J Cancer 39: 2538-2547, 2003.
6. Bange J, Prechtl D, Cheburkin Y, et al: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62: 840-847, 2002.
7. Spinola M, Leoni VP, Tanuma J, et al: FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 14: 415-419, 2005.
8. Spinola M, Leoni V, Pignatiello C, et al: Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 23: 7307-7311, 2005.
9. Wang J, Stockton DW and Ittmann M: The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 10: 6169-6178, 2004.
10. Streit S, Bange J, Fichtner A, Ihrler S, Issing W and Ullrich A: Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111: 213-217, 2004.
11. da Costa Andrade VC, Parise O Jr, Hors CP, de Melo Martins PC, Silva AP and Garicochea B: The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 82: 53-57, 2007.
12. Morimoto Y, Ozaki T, Ouchida M, et al: Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98: 2245-2250, 2003.
13. Becker N, Nieters A and Chang-Claude J: The fibroblast growth factor receptor gene Arg388 allele is not associated with early lymph node metastasis of breast cancer. Cancer Epidemiol Biomarkers Prev 12: 582-583, 2003.
14. Jézéquel P, Campion L, Joalland MP, et al: G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 90: 189-193, 2004.
15. Tanuma J, Hiai H, Shisa H, et al: Carcinogenesis modifier loci in rat tongue are subject to frequent loss of heterozygosity. Int J Cancer 102: 638-642, 2002.
16. Hsieh LL, Wang PF, Chen IH, et al: Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese. Carcinogenesis 22: 1497-1503, 2001.
17. Dupont WD and Plummer WD Jr: Power and sample size calculations: a review and computer program. Control Clin Trials 11: 116-128, 1990.
18. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 3: 457-481, 1958.
19. Peto R and Peto J: Asymptotically efficient rank invariant test procedures. JR Stat Soc [A] 135: 185-206, 1972.
20. Weir BS: Genetic Data Analysis 2. Methods for Discrete Population Genetic Data. Sinauer Associates Inc, Sunderland, 1996.
21. Lohmueller KE, Pearce CL, Pike M, Lander ES and Hirschhorn JN: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33: 177-182, 2003.
22. Boilly B, Vercoutter-Edouart AS, Hondermarck H, Nurcombe V and Bourhis X: FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev 11: 295-302, 2000.
23. Cavallaro U and Christofori G: Multitasking in tumor progression: Signaling functions of cell adhesion molecules. Ann NY Acad Sci 1014: 58-66, 2004.
24. Leung HY, Gullick WJ and Lemoine NR: Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer 59: 667-675, 1994.
25. Jaakkola S, Salmikangas P, Nylund S, et al: Amplification of the FGFR4 gene in human breast and gynaecological cancers. Int J Cancer 54: 378-382, 1983.
26. Webster MK and Donoghue DJ: Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 15: 520-527, 1996.
27. Sibley K, Cuthbert-Heavens D and Knowles MA: Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 20: 4416-4418, 2001.
28. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH and Zwarthoff EC: The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61: 1265-1268, 2001.
29. Boyle JO, Hakim J, Koch W, et al: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53: 4477-4480,1993.
30. Ostwald C, Gogacz P, Hillmann T, et al: p53 mutational spectra are different between squamous cell carcinomas of the lip and the oral cavity. Int J Cancer 88: 82-86, 2000.
31. Saranath D, Tandle AT, Teni TR, et al: p53 inactivation in chewing tobacco-induced oral cancers and leukoplakias from India. Oral Oncol 35: 242-250, 1999.
32. Yang YC, Lu ML, Rao JY, et al: Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer 95: 1455-1458, 2006.